Summary In recent years, radiolabelled monoclonal antibodies have been evaluated for their use in the diagnosis and treatment of neoplastic disease. One isotope which has not been assessed for antibody targeting iS 32P, even though it has many favourable radiobiological characteristics and has been used clinically for the treatment of certain neoplastic disorders such as polycythaemia rubra vera. The main drawback so far in using 32P has been the absence of a general method for phosphorylating antibodies. We have now developed a novel process for the phosphorylation of immunoglobulins which is rapid, efficient and allows high specific activities to be achieved (>l10Ciyg-1). The Recently, however, a novel method for the covalent coupling of the strong chelating group diethylenetriaminepentaacetic acid (DTPA) to antibodies has been developed (Hnatowich et al., 1983a; Scheinberg et al., 1982; Paxton et al., 1985) which allows antibodies to be labelled with metallic radionuclides such as "'1In (Hnatowich et al., 1983a, b; Scheinberg et al., 1982; Paxton et al., 1985) and 99mTC (Lanteigne & Hnatowich, 1984) .
The concept of using monoclonal and polyclonal antibodies to deliver cytotoxic amounts of radiation is now being tested clinically by giving 1311-labelled monoclonal antibodies by the intravenous (Order et al., 1981; Ettinger et al., 1982; Larsen et al., 1983) , intraarterial (Epenetos et al., 1985) and intracavitary (Courtenay-Luck et al., 1984) routes. Although 131I-iodine is not an ideal isotope for antibody targeting, because of its gamma emissions and the high levels of in vivo deiodination (Halpern et al., 1981; Sullivan et al., 1982) , there are still many reasons for its popularity. Most important of these are the availability of protein iodination techniques that are rapid, simple, give high specific activities and which do not damage significantly the antibodies' biological function.
Recently, however, a novel method for the covalent coupling of the strong chelating group diethylenetriaminepentaacetic acid (DTPA) to antibodies has been developed (Hnatowich et al., 1983a; Scheinberg et al., 1982; Paxton et al., 1985) which allows antibodies to be labelled with metallic radionuclides such as "'1In (Hnatowich et al., 1983a, b; Scheinberg et al., 1982; Paxton et al., 1985) and 99mTC (Lanteigne & Hnatowich, 1984) .
More recently another metallic radionuclide, 90Y, has been used to label DTPA-linked antibodies (Hnatowich et al., 1985) and promising radioimmunotherapeutic results have been reported (Order et al., 1986 ). This isotope is of considerable interest because of its pure f-ray particle emission, high emission energy, half-life and stable daughter products. However the use of 90Y does have disadvantages requiring the availability of a 90Sr-90Y generator and, in common with other chelated metallic radionuclides, there is a loss of 90Y from the antibody and large uptake by liver, kidneys, bone and bone marrow (Hnatowich et al., 1985) .
Another isotope with many of the ideal propeties of 90Y is 32p. Though having a longer half-life (14 days) than 90Y, this isotope has been used clinically in cancer therapy for many years (Today's drugs, 1967; Boye et al., 1984 advantageous for attacking tumours with low vascularity. Until now there has been no simple method for conjugating 32p to antibodies. In this communication we describe a simple, rapid procedure for phosphorylating antibodies which allows high specific activities to be achieved without any significant impairment of antibody function. Kemptide (Kemp et al., 1976) (Beavo et al., 1974 N-succinimidyl iodoacetate ester was synthesised as described previously (Rector et al., 1978) .
All other reagents were of analytical grade or better. (60 pl) which had first been diluted with methanol (40 p1). After incubation for 1 h at room temperature, the reaction was shown to be complete by analysis of a sample by thin layer chromatography (Rector et al., 1978) . The absence of ninhydrin-staining material demonstrated the removal of the free primary amino group. The reaction mixture was then used directly for coupling to the thiopropionylated antibody as described below.
The thiopropionylation of monoclonal antibody OX7 and subsequent coupling with iodoacetyl Kemptide was performed as follows: a solution of SPDP (129u1 of a stock solution of 3.6 mg ml -1 in dry DMF) was added to a solution of antibody (27.22 mg) in borate buffer. The molar ratio of SPDP to immunoglobulin was eight. After incubation at room temperature for 1 h, the reaction mixture was desalted on a G50 Sephadex column (60 ml) which had been equilibrated in acetate buffer. Analysis of the eluted protein by the standard method of Carlsson et al. (1978) revealed that 4.6 dithiopropionyl groups had been introduced per IgG molecule. Approximately half the protein solution was then incubated with dithiothreitol (final concentration 50 mM) for 1 h at room temperature and then desalted on a G50 Sephadex column (60ml) equilibrated in nitrogen-flushed phosphate buffer. The eluted protein was immediately concentrated by Amicon ultrafiltration to 1.65 ml (6.8mg ml-1). To this solution was immediately added dry DMF (400 p1) followed by the iodoacetylated Kemptide solution (40p1, prepared as described above). The reaction mixture was incubated at room temperature for 24 h and any remaining unreacted thiol groups blocked by the addition of an excess of N-ethylmaleimide (5mg) in DMF (100 p1). After a further hour, the reaction mixture was applied to G50 Sephadex column (60 ml) equilibrated in the enzyme buffer. The number of Kemptide groups able to accept a phosphate group linked to each antibody molecule was shown to be approximately 2 by trace-labelling studies (see Table I ). The above method was also used for the conjugation of monoclonal antibodies RIO, H17E2 and HMFG2 and bovine IgG fraction (Sigma).
Phosphorylation of OX7-Kemptide For high specific activity labelling, OX7-'Kemptide' (50 ul, 1 mg ml -1) and enzyme buffer (12.5 p1 at 5 times concentration) were added to 1 mCi of
[32P]-y-ATP (1O00 pl), followed by bovine protein kinase (5M1, 50 U). The reaction was incubated at 37°C for 30 min followed by removal of unreacted ATP using a G50 Sephadex column (10ml) equilibrated in phosphate-buffered saline which had been prewashed in PBS containing bovine serum albumin (2mgml-P). Routinely, between 30-40% of the 32P was bound to the conjugate by this process giving specific activities between 5-10 pCipg-1.
For trace-labelling studies, the antibody or conjugate (1 nmol) was treated with ATP (25 nmol), [32P]-y-ATP (0.5pCi) and bovine heart cAMP-dependent protein kinase catalytic subunit (50U) in a total volume of 150pl. After incubating at 37°C for 30min, 10pl samples were taken and added to 100lp1 bovine serum albumin (2mgml-1) in phosphate buffered saline immediately followed by IOOIp 20% trichloroacetic acid. The precipitated protein was collected on GF/C filters (Whatman) For blood clearance studies, BALB/c mice (4/group) were injected i.v. with either radioiodinated OX7 antibody, radioiodinated OX7-Kemptide or OX7-32P-Kemptide, and blood samples taken at various periods of time later. After centrifugation to sediment cells, the protein in 10pl samples of plasma was precipitated with 20% trichloroacetic acid, collected on glass fibre filters and counted in 2ml Optiphase, using an LKB Rackbeta scintillation counter.
Results

Synthesis and labelling of antibody-Kemptide conjugates
The method of conjugating monoclonal antibodies to Kemptide uses the protein-protein coupling chemistry developed by Rector et al. (1978) (Table I) clearly show that the labelling of conjugates is not due to an artifactual non-specific association of 32P-y-ATP with the conjugate.
Analysis of OX7-32P-Kemptide by HPLC showed that 95% of the radioactivity applied to the column co-migrated with OX7-Kemptide. Both the 32P-labelled and unlabelled conjugates had a mobility the same as OX7 and showed no evidence of the presence of significant amounts of dimers or larger polymers (Figure 1 ). The remaining activity had the mobility of (and most probably was) unreacted 32P-y-ATP. Further HPLC analysis of a moderately labelled 0X7-32P-Kemptide sample (3pCigg-' protein) stored in 2mgml-1 BSA in phosphate-buffered saline at 40C demonstrated that there was no rapid dephosphorylation of the conjugate over a 72h period nor was there any evidence of gross radiolytic damage to antibody by the production of labelled antibody fragments.
Kinetic studies on the rapidity of phosphorylation of antibody-Kemptide conjugates have indicated that labelling is complete within 15min (not shown).
Effect of conjugation on antibody-antigen recognition Measurements of the binding of OX7 and OX7-Kemptide to AKR-A lymphoma cells using the FACS (Figure 2) showed that there was no detectable impairment of antigen-binding capacity after the conjugation procedure. The proportions of OX7 and OX7-Kemptide that gave 50% maximal binding was ca. 100 ng 10-6 cells. The results presented in Figure 3 demonstrate the specificity of antibody-targeted 32P_ phosphate. A comparison of 32P-targeting between Kemptide conjugates of OX7 and H 17E2 antibodies on AKR-A cells (Figure 3 ) again demonstrates that only the specific OX7 antibody will allow the localisation of the radionuclide onto the target cell. Further, OX7-32P-Kemptide did not bind detectably to Thy 1.2-expressing EL4 . Figure 1 HPLC analysis of OX7-Kemptide conjugate. A 50pM
sample of the conjugate in enzyme buffer (pH 7.0) was analysed on a TSK G3000 SW column as described in Materials and methods. The radioactivity of 1 ml fractions was counted and the uv absorption recorded. Native OX7 had a mobility identical to that of the conjugate. Silicone oil (Dow Coming)) by centrifugation for 90 sec at 12000g. The centrifuge tubes were frozen on dry ice, the tips containing the cell pellets removed and counted in 2 ml Optiphase. Stability of conjugates in plasma and blood clearance of the OX7-Kemptide conjugates Incubation of a 32P-labelled bovine Ig-Kemptide conjugate in samples of murine, rat and human plasma for up to 64 h (see Materials and methods) gave no indication of dephosphorylation of the conjugate indicating the absence of any Kemptide-recognising phosphatases in the isolated plasma of humans, rats or mice.
In the murine blood clearance study, plasma samples were taken at various time intervals following the injection (i.v.) of either OX7-32P-Kemptide or 12 5I-OX7-Kemptide into mice, and either assessed for acid-precipitable radioactive material or analysed by HPLC. The half-life of OX7-32P-Kemptide in the blood as assessed by acid-precipitation was 2.0 days for the fl-phase clearance (Figure 4 ). This is much shorter than the 4.0 day half-life for 12 5I-labelled OX7 (Figure 4) . Since in parallel studies, 125I-labelled OX7-31P-Kemptide was found to have a half-life of 2.8 days, it seems likely that the shorter half-life of OX7-32P-Kemptide is related to the enhanced clearance of the conjugate compared with the native antibody rather than being the result of dephosphorylation. HPLC analysis of the plasma samples showed that the 32P remained associated with protein which co-migrated with OX7-antibody (not shown).
Discussion
Kemptide, a synthetic heptapeptide substrate for protein kinases, has been covalently bonded to monoclonal antibodies to provide phosphorylatable immunoglobulins which can be used to assess the tumoricidal potential of antibody-targeted 32P. The conjugation method uses the protein-protein coupling chemistry developed by Rector et al. (1978) which has been employed recently to produce antibody-ricin immunotoxins (Thorpe et al., 1984) . Four different monoclonal antibodies as well as a bovine immunoglobulin fraction have been conjugated to Kemptide by this process and as a result are able to accept 1-2 phosphate groups per immunoglobulin molecule from ATP in the presence of appropriate kinases. Using carrier-free 32P_-_ ATP (specific activity >5000Cimmol-1), phosphorylated antibodies with a specific activity of 104Ci g-1 have been achieved. Potentially this could be increased to a theoretical maximum of 30-60 pCi pg-1 if saturation of all the available phosphorylation sites were attained.
None of the antibody-Kemptide conjugates synthesised so far have shown any reduction in antigen-binding activity and thus it seems likely that this conjugation procedure could be usefully extended to other monoclonal antibodies and to non-immunoglobulin proteins as well. The ability of antibody-Kemptide conjugates to act as substrates for protein kinase would also suggest that there is no major impairment of Kemptide phosphate acceptor function although this has not been assessed in detail. The possibility that the phosphorylation of conjugates was a consequence of the conjugation procedure revealing hitherto occluded phosphorylation sites in the antibody molecule was discounted since antibodies that had been through the conjugation procedure in the absence of Kemptide could not be phosphorylated. Studies on the antibody-directed localisation of 32P onto cells clearly showed that the binding of 32P-labelled antibody required the presence of the antigen recognised by the targeting antibody. Non-specific targeting of 32P by antibody-Kemptide conjugates was found to be negligible.
Studies of the stability of antibody-32P-Kemptide conjugates in plasma in vitro show that there is no rapid dephosphorylation of the conjugate by putative plasma phosphatases. However investigation of the blood clearance of OX7-32P-Kemptide in mice showed that the #-phase halflife of the conjugate was only 2.0 days as compared with 4.0 days for l25I-labelled OX7. Parallel studies with 12 II-labelled OX7-3 1P-Kemptide showed that its blood half-life was only 2.8 days. This demonstrates that OX7-Kemptide is cleared more rapidly than native antibody and that the enhanced clearance of the conjugate is not the result of dephosphorylation. The 0.8 day discrepancy between 32P and 125I-measured half-lives can be accounted for by the presence of unconjugated OX7 in the conjugate preparation: the longer blood survival of 125I-labelled unconjugated OX7 would contribute to the half-lives measured by 1251 but would not, of course, have affected those based on the measurement of 32P. The enhanced clearances of antibodyKemptide conjugates would suggest that even apparently minor modifications to the antibody structure can lead to a faster removal of immunoglobulin from the blood. Since HPLC analysis showed an absence of significant amounts of dimers or higher polymers, the enhanced clearance cannot simply be due to the removal of such aggregates.
Although theroretically it would be more attractive to use a linkage involving the more stable carbon phosphorus bond, the preparation of the appropriate reagents at high specific activities presents special difficulties which will not be easily resolved. The novel procedure we describe here has the virtue that it makes use of readily available derivatives of 32P and should allow the therapeutic potential of the targeted radioisotopes to be assessed. Initial studies (to be published elsewhere) have shown that these conjugates can direct 32P to subcutaneous AKR-A tumours achieving concentrations of up to 12.4% of the injected dose/gram. Thus we believe that antibody 32P-Kemptide conjugates represent a new avenue in the development of antibodytargeted tumoricidal agents.
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